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Abstract
The process of maintaining life for the individual is a constant struggle to preserve his/her integrity.
This can come at a price when immunity is involved, namely systemic inflammation. Inflammation
is not per se a negative phenomenon: it is the response of the immune system to the invasion of
viruses or bacteria and other pathogens. During evolution the human organism was set to live 40
or 50 years; today, however, the immune system must remain active for much a longer time. This
very long activity leads to a chronic inflammation that slowly but inexorably damages one or several
organs: this is a typical phenomenon linked to ageing and it is considered the major risk factor for
age-related chronic diseases. Alzheimer's disease, atherosclerosis, diabetes and even sarcopenia
and cancer, just to mention a few – have an important inflammatory component, though disease
progression seems also dependent on the genetic background of individuals. Emerging evidence
suggests that pro-inflammatory genotypes are related to unsuccessful ageing, and, reciprocally,
controlling inflammatory status may allow a better chance of successful ageing. In other words, age-
related diseases are "the price we pay" for a life-long active immune system: this system has also
the potential to harm us later, as its fine tuning becomes compromised. Our immune system has
evolved to control pathogens, so pro-inflammatory responses are likely to be evolutionarily
programmed to resist fatal infections with pathogens aggressively. Thus, inflammatory genotypes
are an important and necessary part of the normal host responses to pathogens in early life, but
the overproduction of inflammatory molecules might also cause immune-related inflammatory
diseases and eventually death later. Therefore, low responder genotypes involved in regulation of
innate defence mechanisms, might better control inflammatory responses and age-related disease
development, resulting in an increased chance of long life survival in a "permissive" environment
with reduced pathogen load, medical care and increased quality of life.
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Innate immune system
The first line of immune defence mainly operates by
detection of a broad range of molecular patterns foreign to
mammalian tissues, called pathogen-associated molecu-
lar patterns that induce the activation of the innate immu-
nity and inflammatory response [1]. The constitutive
expression of a limited set of pattern recognition receptors
by many cell types of the innate immunity does not
require clonal expansion of specific cell populations.
These germ cell-encoded proteins recognize microbial
pathogens or ligands from damaged tissues based on
shared molecular structures and induce host responses
that localize the spread of infection and enhance systemic
resistance to infection. Therefore, the expression of a lim-
ited number of highly active genes during the activation of
innate immunity is able to induce rapid (minutes to
hours) efficient defensive immune responses [2].
Several cell types contribute to innate immunity and the
mononuclear phagocyte lineage plays a pivotal role in
innate immunity. Monocytes, macrophages and their tis-
sue-differentiated derivatives, such as microglia in the
nervous system, express pattern recognition receptors,
namely various scavenger and Toll-like receptors [3].
These receptors induce transmembrane signals that acti-
vate NF-kB and mitogen dependent protein kinase path-
ways [4]. Toll-like receptor activation also induces the
expression of a wide number of genes encoding proteins,
such as cytokines, with regulatory functions upon leuko-
cyte activation and tissue inflammation [5]. Therefore, the
capacity of each individual organism to regulate the acti-
vation of innate immunity and local inflammatory
responses is crucial for initiating defensive action against
pathogens, limiting tissue damage and enhancing fast
recovery and tissue healing.
The inflammatory response
In response to cell injury elicited by trauma or infection
the inflammatory response sets in, constituting a complex
network of molecular and cellular interactions directed to
facilitate a return to physiological homeostasis and tissue
repair. The response is composed of both local events and
a systemic activation mediated by cytokines. If tissue
health is not restored or in response to stable low grade
irritation, inflammation becomes a chronic condition
that continuously damages the surrounding tissues. In
fact, during chronic inflammatory immune responses, tis-
sue injury and healing proceed simultaneously. The col-
lateral damage caused by this type of inflammation
usually accumulates slowly, sometimes asymptomatically
for years but can eventually lead to severe tissue deteriora-
tion [6].
Cytokines are largely secreted molecules that act on the
surrounding microenvironment by providing cell to cell
signalling. Cytokines are components of a large, complex
signalling network. The effects of cytokines on target cells
may be inhibited or enhanced by other cytokines, hor-
mones, and cytokine-receptor antagonists and circulating
receptors. Tumor necrosis factor α  (TNF-α ), Interleukin-1
(IL-1) and IL-6 are the classical pro-inflammatory
cytokines. Their ability to activate both local and systemic
effects is well established. Locally, they contribute to the
activation of the inflammatory cells and together with
chemokines, which induce the expression of adhesion
molecules, cause their local recruitment. When the causes
of the inflammatory reaction are of a high intensity, the
production of cytokines is increased and they are released
in the circulation provoking the "acute phase response".
On the other hand, "inhibitory" cytokines such as IL-10
damp down the activation of some effector functions of T
lymphocytes and mononuclear phagocytes, by inhibiting
the release of pro-inflammatory cytokines and therefore
turning off the inflammatory processes [7,8].
The acute phase response e.g. leukocytosis, fever, somne-
lence, anorexia and acute phase proteins synthesis, such as
C reactive protein (CRP) in the liver, is a highly conserved
inflammatory response which is rapidly activated by
infections or trauma via pattern recognition molecules.
Acute phase protein concentration rapidly increases after
infection, and their production is controlled primarily by
IL-6- and IL-1-type cytokines. The acute phase proteins
provide enhanced protection against microorganisms and
modify inflammatory responses by affecting cell traffick-
ing and mediator release. The more traditional view of
acute phase proteins has extended beyond that of opsoni-
zation of microorganisms. Some acute phase proteins
have anti-inflammatory effects while others have impor-
tant effects on leukocyte activation and trafficking [9].
CRP, named for its capacity to precipitate the somatic C-
polysaccharide of Streptococcus pneumoniae, was the
first acute-phase protein to be described, and is an exqui-
sitely sensitive systemic marker of inflammation and tis-
sue damage. It is a member of the pentraxin family of
plasma proteins, which are part of the lectin fold super-
family of calcium-dependent ligand-binding and lectin
(carbohydrate-binding) proteins. In healthy blood
donors, the median concentration of CRP is 0.8 mg/l, but
following an acute-phase stimulus, values may increase
10 000-fold. In an apparently healthy population the
median baseline value is slightly higher and tends to
increase with age with females showing slightly higher cir-
culating concentrations. In most, but not all diseases, the
circulating value of CRP reflects on-going inflammation
much more accurately than do other biochemical param-
eters of inflammation, such as plasma viscosity or the
erythrocyte sedimentation rate [10].Immunity & Ageing 2005, 2:8 http://www.immunityageing.com/content/2/1/8
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Innate immune system during ageing
Age related changes in clonotypic immune system are well
documented. For instance, involution of the thymus
gland is an early feature of the immune reconfiguration
and several age- related alterations of T or B cell compart-
ments have been described [11-13]. Studies on age-associ-
ated changes of the innate immunity are not as advanced
as those of the clonotypic immune system. However,
investigations from aged mice showed a functional
decline of monocytes and macrophages, a low expression
level of Toll-like receptors from activated splenic and peri-
toneal macrophages and an altered secretion of several
chemokines and cytokines [14,15]. Aged macrophages
also contribute to an impaired the proliferative response
of activated peripheral T lymphocytes [16].
Aged phagocytes, such as macrophages and neutrophils,
showed an impaired respiratory burst and reactive nitro-
gen intermediate production with a decreased ability to
destroy pathogens. Moreover, aged dendritic cells were
less efficient in activating both T and B cell populations
and aged NK cells showed a decreased ability in killing
tumour cells [17,18].
However, not all immune activities are decreased during
ageing. In fact, the 'in vitro' production of pro-inflamma-
tory cytokines, such as IL-1, IL-6 and TNF-α , by mitogen
activated peripheral blood monuclear cells from elderly
persons was higher than that from young donors [19].
Cytokine production may also be up-regulated 'in vivo' in
old subjects resulting in an abnormal elevation of pro-
inflammatory cytokines during inflammatory responses
[20]. An age- related increase of IL-6 levels has also been
reported in plasma, serum and supernatants from healthy
elderly and centenarians [19,21,22]. It is interesting to
note that 'in vitro' addition of IL-1 and TNF-α  to fibrob-
lasts induced an accelerated senescent phenotype which
was rescued by anti-oxidant addition [23].
Inflammatory responses during ageing
A dramatic increase in mean life span and life expectancy,
coupled with a significant reduction in early mortality,
has lead to a large increase in the number of elderly peo-
ple in modern societies. This demographic phenomenon
has been paralleled by an epidemic of chronic disease usu-
ally associated with advancing age [24]. Most age-related
diseases have complex aetiology and pathogenic mecha-
nisms. The clinical diagnosis and therapy of these diseases
requires a multidisciplinary medical approach with pro-
gressively increased costs. A body of experimental and
clinical evidence suggests that the immune system is
implicated, with a variable degree of importance, in
almost all age-related or associated diseases. Both innate
and the clonotypic immune system are usually involved
in the pathogenesis of these chronic diseases [11,25].
However, inflammatory responses appear to be the preva-
lent triggering mechanism driving tissue damage associ-
ated with different age-related diseases and the term
"Inflammaging" has been coined to explain the underlin-
ing inflammatory changes common to most age-associ-
ated diseases [26]. This new term indicates that ageing is
accompanied by an age-dependent up-regulation of the
inflammatory response, due to the chronic antigenic stress
which bombards the innate immune system thorough out
life and potentially triggers the onset of inflammatory
disease.
Chronic inflammation is considered to be involved in the
pathogenesis of all age-related diseases: Alzheimer's dis-
ease, atherosclerosis, diabetes, sarcopenia and cancer all
have important inflammatory components. Inflammag-
ing, i.e. the up-regulation of a variety of anti-stress
responses at the cellular and molecular level, is the conse-
quence of the body's ability to counteract and modulate
the effects of a variety of stressors, which cause the accu-
mulation of molecular and cellular scars [26,27]. How-
ever, as recently discussed [28], a wide range of different
aetiological factors is likely to contribute to increased low-
grade inflammatory activity in elderly populations includ-
ing a decreased production of sex steroids, smoking, sub-
clinical disorders such as arteriosclerosis, asymptomatic
bacteruria and a higher relative/absolute amount of fat tis-
sue, which has been suggested to produce pro-inflamma-
tory cytokines [29] (see below). Furthermore, increased
levels of circulating inflammatory mediators may result
from a constant, low-grade activation of cytokine-produc-
ing cells or a dysregulated cytokine response following
stimulation [28], which does not readily become damped
down. On the other hand, a recent hypothesis suggests
that the reduction in lifetime exposure to infectious dis-
eases and other sources of inflammation – the cohort
mechanism – may also contribute to the historical decline
in old-age mortality [30].
Recent studies have linked an individual's exposure to
past infection to levels of chronic inflammation and to
increased risk of heart attack, stroke, and cancer. For
example, the risk of heart attack is correlated with serum
levels of inflammatory proteins such as CRP [31]. Within
individuals, CRP levels are also correlated with the
number of seropositivities to common pathogens, sugges-
tive of infection history [32].
Low-grade increases in levels of circulating TNF-α , IL-6,
soluble IL-2 receptor (sIL-2R), and CRP and low levels of
albumin and cholesterol, which also act as inflammatory
markers, are strong predictors of all-cause mortality risk in
several longitudinal studies of elderly cohorts. The effects
of inflammatory mediators upon survival are independ-
ent of pre-existing morbidity and other traditional riskImmunity & Ageing 2005, 2:8 http://www.immunityageing.com/content/2/1/8
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factors for death (smoking, blood pressure, physical exer-
cise, total cholesterol, co-morbidity, body mass index, and
intake of anti-inflammatory drugs) suggesting that
cytokines may induce exaggerated pathological processes.
Furthermore these molecules appear to be sensitive mark-
ers of pre-clinical disorders in elderly populations [28,33-
39].
In the following sections we will focus on the role of
innate immunity and inflammation in the most common
diseases of elderly in order to direct the reader's interest to
these emerging topics in modern gerontology and geriat-
rics investigations.
Frailty and sarcopenia
Frailty has been defined as an age-related decline in lean
body mass, decreased muscle strength, endurance, bal-
ance and walking performance, low activity and weight
loss accompanied by a high risk of disability, falls, hospi-
talisation and mortality [28,40]. It has been suggested that
this syndrome reflects a metabolic imbalance caused by
overproduction of catabolic cytokines and by the dimin-
ished availability or action of anabolic hormones, result-
ing from ageing itself and the presence of associated
chronic conditions [28,41]. Sarcopenia is obviously a cen-
tral part of the frailty syndrome [28]. Sarcopenia is the loss
of muscle mass and strength that occurs with normal age-
ing. In elderly, there is a decline in a variety of neural, hor-
monal, and environmental trophic signals to muscle.
However, the most important endogenous cause may be
the irreversible age-related loss of α -motor units in the
central nervous system [42-44]. The most important envi-
ronmental cause of sarcopenia is lack of physical activity
which is an age-related phenomenon which shows uni-
versal decline with age in industrialized societies; obesity
and type 2 diabetes being concomitant epidemics (see
below). An emerging issue in the past few years for sarco-
penia research has been whether there is also an increased
catabolic signal, driven by systemic inflammation [44].
Systemic low-grade inflammation has been associated
with decreased muscle mass as well as the development of
functional disability in elderly populations [33,44-47].
TNF-α  has special effects that may contribute directly to
sarcopenia [44], including increased basal energy expend-
iture, anorexia, loss of muscle and bone mass 'in vivo' and
association with wasting/cachexia in chronic inflamma-
tory disorders. Consistent with these findings, muscle pro-
tein synthesis was inversely related to local levels of TNF-
α  protein in skeletal muscles in frail very old humans [48].
In a recent study of nursing home residents aged 85–96
years, systemic low-grade activation of the TNF-α  system
at baseline was inversely correlated to muscle strength
after resistance training for 12 weeks, demonstrating that
TNF-α  could also be a limiting factor for training-induced
improvement in muscle strength in very old people [49].
The role of IL-6 in sarcopenia is not clear. Epidemiological
studies have reported that IL-6 is strongly associated with
functional disability and loss of muscle mass but experi-
mental studies have not been able to link IL-6 to sarcope-
nia [28,44]. Human investigations have shown that
inflammation impairs muscle strength in elderly people
[50] while Insulin Growth Factor 1 and IL-6 plasma levels
were synergistically related to disability and mortality in
older women [51].
A complicating factor in untangling the cause-effect rela-
tionships underlying sarcopenia is the ability of IL-6, TNF-
α , physical inactivity, abdominal obesity, and other fac-
tors to cause insulin resistance in the elderly [52-54]. Loss
of control of the anabolic action of insulin on muscle
would be another factor favouring sarcopenia, resulting in
the elevation of one or more catabolic signals. Thus, the
weight gain that occurs in most adults during middle age
may actually predispose to sarcopenia as they age [44].
Obesity, the metabolic syndrome, type II 
diabetes
Western societies face a health care crisis of epidemic pro-
portion, since the number of people with the metabolic
syndrome is rising exponentially. This condition consti-
tutes a major challenge for public health professionals in
the field of preventive medicine and estimates suggest that
more than 40 million US adults will be affected by the
syndrome [55].
There is not known survival advantage of morbid obesity;
on the other hand increased body fat is linked to high
mortality [56]. In the past, humans have been plagued by
famine when survival advantage would have been con-
ferred by genes favouring an available energy source: the
so called 'thrifty gene' hypothesis. These genes led to
genetic selection toward insulin resistance in the periph-
eral tissue in order to preserve glucose supply of the brain
during starvation [57]. Human obesity shows a clear
genetic component, which is usually polygenic and poly-
morphic variances in a number of 'thrifty' genes could
contribute to different susceptibilities to obesity and dia-
betes [58,59].
Metabolic syndrome may be detected by 5 clinical diag-
nostic criteria 1) abdominal adiposity, 2) hypertriglyceri-
demia, 3) low high density lipoprotein, 4) hypertension,
5) fasting hyperglycaemia [55].
An involvement of inflammation with pathogenic mech-
anisms influencing the development of the metabolic syn-
drome has been suggested [55,60,61] and elevated CRP,
IL-6 and TNF-α , associated with visceral adiposity, have
been reported in this syndrome [61]. Adipocytes constitu-
tively express the pro-inflammatory TNF-α  [54] whichImmunity & Ageing 2005, 2:8 http://www.immunityageing.com/content/2/1/8
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decreases after weight loss [62]. Further work in this area
has confirmed increased plasma concentrations of CRP,
IL-6, and plasminogen activator inhibitor-1 (PAI-1) [63-
65]. Therefore, a complex interplay may exist between
inflammatory responses and general metabolism in
atherosclerosis, cardiovascular disease, metabolic
syndrome.
It is becoming clear that the increased adipose tissue is not
a simple reservoir for excess nutrients, but rather an active
and dynamic organ capable of expressing several
cytokines and other fat-derived peptides (FDP). Some
FDP may have a role in the development of the metabolic
syndrome but there is no evidence that these FDP are
directly causing inflammation. It has been suggested that
high levels of inflammatory factors are markers for obes-
ity/abdominal obesity seen with aging, but some of these
may not necessarily have a causative role in the develop-
ment of inflammation [29]. Alternatively, a positive corre-
lation was found between the body mass index and the
percentage of resident macrophages, suggesting that fat
tissue growth is associated with a recruitment of blood
monocytes, responsible for cytokine production [66].
Insulin resistance is due to the reduced ability of periph-
eral tissues to properly respond to the activation induced
by insulin. It is a key feature in the pathogenesis of type II
diabetes and this condition may precede by 10–20 years
the onset of hyperglycaemia and the clinical manifesta-
tion of the disease. Recent data suggests that a defect in
insulin activation of glucose transportation in muscle cells
could be induced by serine kinase cascade activation,
which is down stream mediators of tissue inflammation
factors [67].
Data from the Insulin Resistance Atherosclerosis Study
showed that insulin resistance, as assessed by frequently
sampled glucose tolerance tests, correlated with high
blood levels of CRP, fibrinogen and PAI-1 and levels of
these inflammatory factors were predictors of type II dia-
betes development [68]. Increased blood concentrations
of TNF-α  and IL-6 were associated with obesity and type II
diabetes [69]. Finally, results of the population study from
the European Prospective Investigation into Cancer and
Nutrition Potsdam indicated a significant interaction
between plasma IL-1β , IL-6 and type II diabetes develop-
ment. In fact subjects with detectable IL-1β  levels and
increased levels of IL-6 showed an independently elevated
risk of developing the disease [70].
Inflammation may predispose to a pre-diabetic state by
increasing insulin resistance, since pre-diabetic subjects
showed increased plasma levels of inflammatory proteins
without primary defects of beta cell functions [71]. Sub-
clinical inflammation was found significantly related to
insulin resistance in a high risk group for diabetes, i.e. in
subjects with positive family history of diabetes, obesity
and hyper or dyslipoproteinemia [72]. Recent results from
the INCHIANTI population study showed that subjects in
the upper tertile of insulin resistance had increased serum
levels of TNF-α , IL-1R antagonist and IL-6 and low levels
of sIL-6R [73].
TNF-α  causes an inhibition of auto-phosphorylation of
tyrosine residues of the insulin receptor (IR) and an
induction of serine phosphorylation of insulin receptor
substrate-1, which in turn causes serine phosphorylation
of the IR in adipocytes and inhibits tyrosine phosphoryla-
tion [74]. More recently, IL-6 has been shown to inhibit
insulin signal transduction in hepatocytes [53]. Therefore,
cytokines show relevant metabolic effects.
Novel data have now appeared showing that the concom-
itant presence of the promoter polymorphisms of TNF-α
and IL-6, linked to high production of these cytokines
increases the risk of conversion to type 2 diabetes in obese
subjects with impaired glucose tolerance response [75].
As discussed by Dandona et al. [69], two mechanisms
might be involved in the pathogenesis of inflammation.
Glucose and macronutrient intake causes oxidative stress
and inflammatory changes. Chronic overnutrition (obes-
ity) might thus be a pro-inflammatory state with oxidative
stress. The increased concentrations of TNF-α  and IL-6,
associated with obesity and type 2 diabetes, might inter-
fere with insulin action by suppressing insulin signal
transduction, which in turn might promote inflamma-
tion. In fact, insulin reduces ROS generation by mononu-
clear cells, suppresses NADPH oxidase expression and
intranuclear NF-kB binding, induces IkB expression and
suppresses some inflammatory molecules [69,76].
The well-known beneficial effects of caloric restriction on
longevity in animal models by inducing reduced visceral
fat mass might also induce a reduced secretion of multiple
metabolically active factors, which are potentially respon-
sible for the development of insulin resistance. This
decrease in fat mass and its beneficial effects observed in
ageing animal models might apply also to human ageing
and its related pathology [77].
Cancer diseases
The majority of cancer occurs in subjects over the age of 65
years. Cancer rates increase sharply with age in both sexes:
the incidence of cancer is 12–36 times higher in individu-
als aged 65 years or older compared with individuals aged
25–44 years, and 2–3 times more common than in per-
sons aged 45–64 years. It is worth noting that 70% of
deaths attributable to all cancer occur in men and in
women aged 65 years or older whereas 35% cancer deathsImmunity & Ageing 2005, 2:8 http://www.immunityageing.com/content/2/1/8
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in men and 46% of cancer deaths in women occur in
those aged 75 years or older. The relationship between
ageing and cancer is similar for most cancers, and it is well
described by the multistage model. So, ageing might be
considered not as a determinant of cancer per se, but as a
surrogate marker of the duration of exposure to relevant
carcinogenic factors [78-80].
Chronic inflammation induced by either biological,
chemical, mechanical or physical injuries has been associ-
ated with increased incidence of cancer in different
human tissues [81]. For instance, inflammatory bowel
disease, ulcerative colitis and Crohn's disease are clinical
conditions predisposing to cancer development of the
large bowel or terminal ileum [81,82].
Helicobacter pylori microorganisms are associated with
atrophic gastritis, mucosal dysplasia, gastric adenocarci-
noma and an unusual form of gastric lymphoma [81,82].
Schistosome and trematode infections have been associ-
ated with cancers of the bladder and the biliary tracts [81].
The recognition of a role for inflammation in the natural
history of a tumor has been known stretching from the
mid-19th century [83]. The inflammatory microenviron-
ment of tumors is characterised by the presence of host
leucocytes both in the supporting stroma and in the
tumor area [84]. The question whether the inflammatory
infiltrate helps or hinders tumors is still open. In fact,
inflammatory cells and cytokines found in tumors can
contribute to tumor growth, progression, and immuno-
suppression as well mounting an effective host anti-tumor
response. However, in most cases inflammation plays a
role in the development of solid cancer. That is clearly
demonstrated by a prospective, nested case-control study
of a cohort of 22,887 adults followed for 11 years. A total
of 172 colorectal cancer cases were identified. Up to 2 con-
trols (n = 342) were selected for each case and matched by
age, sex, race, and date of blood draw. Plasma CRP con-
centrations were higher among all colorectal cases com-
bined compared with controls and the risk of colon cancer
was higher in persons in the highest vs. lowest quartile of
CRP [85].
Furthermore, in another recent study, a total of 174
patients considered to have undergone curative resection
for cancer were studied. The results show that raised circu-
lating concentrations of CRP, whether measured before or
after operation, predict overall and cancer-specific sur-
vival in patients undergoing potentially curative surgery
for colorectal cancer suggesting that the presence of a sys-
temic inflammatory response predicts a poor outcome
[86]. This data supports the hypothesis that inflammation
is a risk factor for the development of some kind of solid
tumors such as colon cancer.
Cancer susceptibility and severity may also be associated
with functional polymorphisms of cytokine genes
involved in regulation of inflammation. In particular, as
discussed in a recent review [79], a considerable body of
data indicates that particular cytokine polymorphisms,
especially those involving IL-6 and IL-10 genes, may influ-
ence susceptibility to, and in some cases prognosis in neo-
plastic diseases. It is intriguing that these two cytokines are
involved in longevity [87-89]. Discrepant results might
depend on confounding factors that affect case-control
studies [90] or as discussed by Caruso et al. [79] might
also depend on pleiotropic action of cytokines. It is para-
digmatic in this respect that the favourable effect of high
producer IL-10 genotype on hepatocarcinoma induced by
HBV [91], may be due to the relative lack of control of
HBV infection by immunosuppressive effects of high IL-
10 levels.
On the other hand, several and diverse mechanisms may
link inflammation to cancer.
1) Free radical production, derived by oxygen or NO met-
abolic pathways; the respiratory burst of leukocytes, and
the arachidonic acid cascade activation are strongly impli-
cated in DNA modification and protein damage which in
turn promotes carcinogenesis [92].
2) High constitutive hyper-expression of NF-kB, an ubiq-
uitous transcription factor with regulatory effect upon dif-
ferent inflammatory, apoptotic and oncogenic genes [82].
3) Alterations of the p53 gene induced by NO derived rad-
icals promoting clonal expansion of aberrant or mutated
cells [92].
4) Induction of angiogenesis by inflammatory factors
favouring cancer progression [92].
5) Increased release of key pro-inflammatory factors and
some cytokines, such as IL-1β , TNF-α  and interferon
(IFN)-γ , implicated in both the regulation of inflamma-
tion and the development of cancer [92,93].
Atherosclerosis and cardiovascular diseases
Atherosclerosis and its complications are a major problem
contributing to large sections of morbidity and mortality
in old people. Cardiovascular disease is the leading world-
wide cause of morbidity and death in Western societies
[94]. However, our understanding of pathogenic mecha-
nisms underling atherosclerosis and its complications is
still incomplete, since more than half of patients with
atherosclerosis do not show classical risk factors, such as
hypercholesterolemia, hypertension, history of smoking,
diabetes, obesity and sedentary life style [94,95].Immunity & Ageing 2005, 2:8 http://www.immunityageing.com/content/2/1/8
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On the other hand, atherosclerosis, formerly considered
an inocuous lipid storage disease, actually involves an
ongoing inflammatory response (Figure 1). Recent
advances in basic science have established a fundamental
role for innate immunity in mediating all stages of this
disease from initiation through progression and, ulti-
mately, the thrombotic complications of atherosclerosis
[96-98]. Clinical studies have shown that the emerging
biology of inflammation in atherosclerosis applies
directly to human patients. Elevation in markers of
inflammation predicts outcomes of patients with acute
coronary syndromes, independently of myocardial dam-
age. In addition, low-grade chronic inflammation, as indi-
cated by levels of the inflammatory marker CRP and
cytokines, prospectively defines risk of atherosclerotic
complications, thus adding to prognostic information
provided by traditional risk factors. In fact, levels of CRP
or IL-6 have been suggested as significant predictive risk
factors for future development of cardiovascular events
[31,95,99-103]. Increased levels of serum IL-1β  have also
been associated with high risk of congestive heart failure
and angina pectoris [104]. Altered level of IL-1β  is also
suggested to be implicated in chronic inflammation
underlining high blood pressure [105].
An initiating event is the accumulation of lipids in the ves-
sel wall, which subsequently will become modified and
triggers an inflammatory process. Low-density lipopro-
teins (LDL) are taken up by macrophages through scaven-
ger receptors, leading to foam cells; the lipid deposits
become oxidized forming pro-inflammatory lipid perox-
ides. Monocytes are attracted from the blood and differen-
tiate into macrophages that take up the modified LDL and
form lipid-laden foam cells, which is the first hallmark of
Schematic representation of inflammatory mechanisms involved in pathogenesis of atherosclerosis and plaque formation Figure 1
Schematic representation of inflammatory mechanisms involved in pathogenesis of atherosclerosis and plaque formation. 
Monocytes and macrophages are the protagonists of atherosclerotic processes.Immunity & Ageing 2005, 2:8 http://www.immunityageing.com/content/2/1/8
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atherosclerotic plaque development. Later on, inflamma-
tory mediators increase, other immune cells are attracted,
and smooth muscle cells are activated and become
involved. More advanced stages of plaque development
are characterized by increased deposition of extra cellular
lipid cores, fibrous material, and often necrosis. Subse-
quently, these macrophages are further activated, leading
to the production of a wide range of cytokines and growth
factors. Myocardial infarction may occur as a result of ero-
sion or uneven thinning and rupture of the fibrous cap,
often at the shoulders of the lesion where macrophages
enter, accumulate and are activated and where apoptosis
may occur [7,96-98].
Because genetic traits contribute significantly to the risk of
coronary heart disease [106], a number of studies have
now addressed the hypothesis that allelic variations in
genes of innate immunity may increase the risk of this dis-
ease [107,108]. Differences in the genetic regulation of
inflammatory processes might partially explain why some
people, but not others, develop the disease and why some
develop a greater inflammatory response than others.
Accordingly, common gene polymorphisms controlling
high production of inflammatory molecules have been
associated with atherosclerosis and a good control of
inflammation might play a protective role against athero-
sclerosis [107-110]. Recently, a combination of alleles in
different inflammatory genes has been associated with
increased risk of developing acute myocardial infarction
in elderly men [111].
In addition to innate immunity, clonotypic immunity
plays also a role in atherosclerosis. Recent findings sup-
port the hypothesis that a crucial component of athero-
sclerosis is represented by T cell-mediated immune
responses that are inappropriate in terms of time of onset,
intensity, and target [112]. On the other hand, the most
direct evidence for the critical role for T cells, IFN-γ , and
IFN-γ -driven molecules in atherosclerosis is provided by
mice with combined deficiencies of apolipoprotein E
(apoE) and the IFN-γ  receptor, in which the development
of atheroma is significantly reduced in comparison to
mice with only apoE deficiency, whereas exogenous IFN-γ
enhances atherosclerosis [113,114]. In contrast, the role
of B cells has remained unclear. B-cells are not always
present and may be protective. In fact, recent studies sug-
gest that this cell type may inhibitthe development of vas-
cular pathology in models of atherosclerosisand
restenosis [115]. Finally, Wick et al. [116] have developed
an  autoimmune-inflammatory  concept of atherogenesis
based on experimental and clinical models. They argue
that atherosclerosis may be the price humans pay for pre-
existing immunity to microbial or autologous heat shock
protein (HSP) 60. In summary, their autoimmune
hypothesis of atherogenesis postulates that HSP60 expres-
sion is induced in arterial endothelial cells as a response
to the action of stress factors, notably the classical athero-
sclerotic risk factors. Autologous HSP60 epitopes exposed
on the surface of stressed endothelial cells are recognized
by either pre-existing humoral and cellular anti-microbial
HSP60 immune reactions or by invoking bona fide
autoimmunity based on exposure of altered autologous
HSP60 epitopes. The authors accept the importance of
well-established atherosclerotic risk factors during athero-
genesis, but assign a new role for them in the earliest
stages of the disease, viz. acting as stressors [116].
Brain degenerative diseases: Alzheimer's 
disease
Alzheimer's disease (AD), a heterogeneous and progres-
sive neurodegenerative disease which in Western societies
mainly accounts for clinical dementia, is expected in the
USA to rise from 4.6 today to 16 millions cases in 2050
[117]. Neuro-pathological hallmarks of AD are neuronal
and synapsis loss, extracellular amyloid deposits (neuritic
plaques) and intracellular deposition of degenerate fila-
ments (neurofibrillary tangles) [118]. Major clinical man-
ifestations of the disease are memory loss and cognitive
impairment [119].
Inflammation clearly occurs in pathologically vulnerable
regions of the AD brain, and it does so with the full com-
plexity of local peripheral inflammatory responses. In the
periphery, degenerating tissue and the deposition of
highly insoluble abnormal materials are classical stimu-
lants of inflammation. Likewise, in the AD brain damaged
neurons and neuritis, highly insoluble Aβ 42 peptide
deposits and neurofibrillary tangles provide obvious stim-
uli for inflammation. Senile plaques in AD brains are
associated with reactive astrocytes and activated micro-
glial cells; cytokines and acute phase proteins are also
overexpressed in microglia and astrocytes surrounding
neuropathological lesions in AD brains. Inflammatory
factors, such as cytokines, chemokines, complement com-
ponents and acute phase proteins co-localize as secondary
components in neuritic or senile plaques, or are over-pro-
duced in AD brains. Finally, activated microglia surrounds
senile plaques and areas of neurodegeneration [120,121].
There is accumulating evidence that Aβ  peptide may pro-
mote or exacerbate inflammation by inducing glial cells to
release immune mediators. Moreover, microglial and
astroglial cells surrounding mature plaques in AD brains
have been found to express activation markers. Enriched
populations of human microglial cells isolated from
mixed cell cultures prepared from embryonic human tel-
encephalon tissues are able to express constitutively
mRNA transcripts for cytokines and chemokines and
treatment with pro-inflammatory stimuli as lipopolysac-
charide or Aβ  peptide leads to increased expression of
mRNA levels of these inflammatory molecules [122].Immunity & Ageing 2005, 2:8 http://www.immunityageing.com/content/2/1/8
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The role of inflammation is further emphasized by a
number of epidemiological studies demonstrating that
the long-term use of nonsteroidal anti-inflammatory
drugs may protect against AD. There are now a several
published observational studies demonstrating that peo-
ple who are known to be taking anti-inflammatory drugs
considerably reduce their odds of developing AD and
population studies have confirmed this negative associa-
tion [123]. However, alternative hypothesises have been
proposed. In particular, this effect has been hypothesised
as relating to the ability of these drugs to inhibit angiogen-
esis. In fact, the brain endothelium secretes the precursor
substrate for the β -amyloid plaque and a neurotoxic pep-
tide that selectively kills cortical neurons. So, antiang-
iogenic drugs targeting the abnormal brain endothelial
cell might be able to prevent and treat this disease [124]
The long-term prospective association between dementia
and the well known inflammation marker CRP was eval-
uated in a cohort of Japanese American men. These sub-
jects were seen in the second examination of the
Honolulu Heart Program (1968–1970) and subsequently
were re-examined 25 years later for dementia in the Hono-
lulu-Asia Aging Study (1991–1996). In a random subsam-
ple of 1,050 Honolulu-Asia Aging Study cases and
noncases, high-sensitivity CRP concentrations were meas-
ured from serum taken at the second examination;
dementia was assessed in a clinical examination that
included neuroimaging and neuropsychological testing
and was evaluated using international criteria. Compared
with men in the lowest quartile (<0.34 mg/L) of high-sen-
sitivity CRP, men in the upper three quartiles had a 3-fold
significantly increased risk for all dementias, mainly
Alzheimer's disease and vascular dementia. These data
support the view that inflammatory markers may reflect
not only peripheral disease, but also cerebral disease
mechanisms related to dementia, and that these processes
are measurable long before clinical symptoms appear
[125].
On the other hand, several other investigations have
shown increased blood levels of some cytokines, such as
IL-1β  and IL-6, and acute phase proteins α -1-antichymot-
rypsin, (ACT) in patients with clinical AD [126-129].
Therefore, altered immune responses in the brain and the
peripheral blood appeared to be associated with the dis-
ease. Finally, plasma levels of ACT also correlated with the
degree of cognitive impairment in AD patients from a
case-control study [126] suggesting that peripheral mark-
ers of inflammation or impaired immune responses could
be used for monitoring the progression of the disease.
Elevated levels of IL-6 in both brain homogenates and
peripheral blood from AD patients have also been
reported [130]. These findings suggest that an important,
but still largely unknown, interplay between brain and
peripheral immune responses may exist in the disease.
In conclusion, the brain lesions associated with AD,
which are referred to as neurofibrillary tangles and senile
plaques, are characterized by the presence of a broad spec-
trum of inflammatory mediators, produced by resident
brain cells, including neurons. Although secondary to the
fundamental pathology caused by the presence of tangles
and plaques, there is strong evidence that inflammation
exacerbates the neuronal loss. Accordingly, several reports
have appeared indicating that the risk of AD is substan-
tially influenced by several polymorphisms in the pro-
moter region, and other untranslated regions, of genes
encoding inflammatory mediators. Alleles that favour
increased expression of the inflammatory mediators or
alleles that favour decreased expression of anti-inflamma-
tory mediators are more frequent in patients with AD than
in controls. The polymorphisms are fairly common in the
general population, so there is a strong likelihood that any
given individual will inherit one or more of the high-risk
alleles [121,127,129-135] (Figure 2).
Conclusion
In this presentation we have presented evidence linking
innate immunity with the pathogenesis of age-related
chronic degenerative diseases. Inflammation may be a
pivotal and common background shared by the majority
of these pathological conditions. Although evidence
already presented has focused on innate immunity, clono-
typic immunity has support as an emerging mechanism
related to the pathogenesis of these diseases [116].
The evidence that a decline in mortality exists when com-
paring Swedish cohorts born in the middle of the 18th cen-
tury to those in the 20th suggests important links between
mortality in old age and in early life. Cohort mortality
during childhood has been linked to cohort mortality in
old age, implying that early exposure to infection is
important in determining and imprinting the cohort mor-
bidity phenotype [30]. Thus, chronic inflammatory mech-
anisms carry the imprint of early-life infections into later
life morbidity and mortality. Evidence presented suggests
that serological indicators of infection and inflammation
in present day populations are related to vascular disease
and other morbidities of ageing. Such inflammatory
responses can be induced by invading pathogens, as well
as by trauma or internal tissue injury. Thus, adaptive
responses to short term infections or injury can become
maladaptive as life progresses -a double-edged sword that
evolutionary biologists refer to as antagonistic pleiotropy
[136].
The process of life for the individual is the struggle to pre-
serve its biological and immunological integrity.Immunity & Ageing 2005, 2:8 http://www.immunityageing.com/content/2/1/8
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However, the preservation of the integrity of the organism
comes with the price of responsiveness to systemic inflam-
mation [137] which must be finely tuned otherwise dys-
regulation becomes a damaging accompanynt. With
ageing, the reason why the innate immune system
becomes over-activated is not clear, but increased expo-
sure to infectious agents or cumulative damage to tissues
could spark the change. Inflammation is not 'per se' a neg-
ative phenomenon: it is the response of the immune sys-
tem to pathogenic viruses or bacteria. Thorough out
Alzheimer's disease: amyloid deposition is one the main pathogenetic mechanism Figure 2
Alzheimer's disease: amyloid deposition is one the main pathogenetic mechanism. Accumulation of Aβ  peptide may be caused 
by 1) gene mutations (PS1, PS2 and APP human mutations in familial Alzheimer's disease) 2) genotype (and/or phenotype) 
favoring unbalanced inflammatory responses (pro-inflammatory genotype/anti-inflammatory genotype).Immunity & Ageing 2005, 2:8 http://www.immunityageing.com/content/2/1/8
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evolution, man has been set to live about 40 or 50 years
but in today's world the immune system is active for sev-
eral decades compared with the past centuries. A long
period of activitation may lead to chronic inflammation
which inexorably damages several/all organs and is the
phenotype linked to both ageing and chronic disease. In
cardiovascular disease, conventional risk factors remain
important, but differential baselines in inflammatory sta-
tus may explain why cholesterol levels seem not always
directly associated with cardiovascular disease [22,109].
Low-grade inflammation is also associated with parame-
ters such as obesity, smoking, and physical inactivity, so
inflammatory mediators constitute a link between life
style factors, infections and physiological changes in the
process of ageing on the one hand, and risk factors for age-
related diseases on the other [28]. This immune response
also depends on the genetic background of individuals. In
fact, emerging evidence suggests that polymorphic alleles
of inflammatory cytokines, involved in high cytokine pro-
duction, are related to 'unsuccessful' ageing as noted pre-
viously with respect to atherosclerosis and AD. On the
other hand, controlling inflammatory status may enhance
individual chance of achieving 'successful' ageing. So,
major findings reporting a relationship between cytokine
polymorphisms and longevity suggest that those individ-
uals who are genetically predisposed to produce low levels
of inflammatory cytokines or high levels of anti-inflam-
matory cytokines may have an increased capacity to reach
the extreme limit of human life-span [87-
89,109,138,139].
In other words, age-related diseases are "the price we pay"
for an active immune system that defends us in youth but
may harm us later on [139,140]. Such data support the
notion that antagonistic pleiotropy [136] plays a relevant
role in diseases and longevity. Pro-inflammatory geno-
types may therefore be both friends and foes. They are an
important and necessary part of the normal host
responses to pathogens, but the overproduction of
inflammatory molecules may aggravate immune-inflam-
matory-related disease and contribute to earlier death. An
immune system evolved to control pathogens is likely to
favour a highly charged pro-inflammatory response pro-
grammed to resist fatal infections with avoidance of early
mortality. However, persons with low responder geno-
types may risk earlier mortality in response to serious
infection but if they survive may respond less aggressively
to age-related disease development. Such conditions
might result in an increased chance of longevity in an
environment with reduced pathogenic antigen load and/
or adequate medical treatment [139,141,142].
Further studies on this field will open the way for new
diagnostic approaches for early diagnosis of relevant pre-
clinical states of age-related diseases. It may be possible,
before clinical manifestations appear, that anti-inflamma-
tory or other treatments might play a decisive role in pre-
venting or significantly retarding the manifestation of the
disease. Other studies focused on clarifying the specific
contribution of each immune factor to a given disease will
also contribute to the discovery of new drugs and/or inno-
vative intervention protocols specific for these diseases
related to ageing.
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